research use only
Cat.No.S4029
| Related Targets | Integrase Antibiotics Anti-infection Fungal Antiviral COVID-19 Parasite Reverse Transcriptase HIV HCV Protease |
|---|---|
| Other Bacterial Inhibitors | Berberine BTZ043 Racemate Teicoplanin Pefloxacin Mesylate Ornidazole Proanthocyanidins Solithromycin Skatole Berberine Sulfate Furagin |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 1400.63 | Formula | C52H98N16O13.5/2H2SO4 |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 1264-72-8 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | Polymixin E Sulfate | Smiles | CCC(C)CCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O)C(C)O.CCC(C)CCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC2CC | ||
| In vitro |
Colistin (2 μg/mL) is active against most strains of Escherichia coli and P. aeruginosa, and all species of Enterobacter, Salmonella, Shigella, Pasteurella, Brucella, and Bordetella. Proteus, Serratia, Providencia. Colistin inhibits 225 strains of P.aeruginosa with MIC90 and MIC50 of 6.3 μg/mL and 1.6μg/mL, respectively. Colistin sulfate is approved only for topical and oral use because of its toxicity. Colistin sulfate is administered orally (tablets or syrup) for bowel decontamination and topically as a powder for the treatment of bacterial skin infections. Colistin interacts with the bacterial membrane through electrostatic interactions between the cationic polypeptide (colistin) and anionic lipopolysaccharide (LPS) molecules in the outer membrane of the gram-negative bacteria, leading to derangement of the cell membrane. Colistin displaces magnesium (Mg+2) and calcium (Ca+2), which normally stabilize the LPS molecules, from the negatively charged LPS, leading to a local disturbance of the outer membrane. Colistin has also potent anti-endotoxin activity. Colistin sulfate produces a strong postantibiotic effects against Acinetobacter baumannii ranging from 2.5 hours to 7.0 hours in a concentration-dependent manner.
|
|---|---|
| In vivo |
Colistin sulfate (5%, i.m.) causes the muscle circumference to appear erythematic in mice. Colistin sulfate (i.m., 15 mg/kg/day for 5 days) causes obvious neurotoxicity to piglets with moderate granular degenerations in the epithelial tissues from kidney and liver of mice. Colistin sulfate (i.m.) at dose of 2.5 mg/kg and 5.0 mg/kg results in Cmax of 3.73 mg/mL and 6.40 mg/mL, Tmax of 32 min and 34 min, t(1/2beta) of 256 min and 264 min, and absolute bioavailability of 95.94% and 88.45% in mice.
|
References |
|
(data from https://clinicaltrials.gov, updated on 2024-05-22)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT06087536 | Not yet recruiting | Hospital-acquired Bacterial Pneumonia|Ventilator-associated Bacterial Pneumonia |
Omnix Medical Ltd |
January 2024 | Phase 2 |
| NCT05542446 | Terminated | Colistin |
St. Anne''s University Hospital Brno Czech Republic|Palacky University |
September 1 2022 | Phase 4 |
| NCT04775238 | Unknown status | Nosocomial Infections |
Sohag University |
February 27 2021 | Not Applicable |
| NCT04208945 | Unknown status | Pneumonia Ventilator-associated|Gram-Negative Pneumonia |
University of Thessaly |
December 2019 | Not Applicable |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.